Extensive Study of DFT-Quantum Calculations Based QSAR Modeling of Fused 1,2,4-Triazine Derivatives Revealed Potent CYP1A1 Inhibitors

In a continuing effort for our research group, we identify new active 1,2,4-triazine derivatives as novel cancer preventive agents that target CYP1A1 activity, through the application of quantitative structure–activity relationship (QSAR) theory. For this purpose, novel fused 1,2,4-triazine derivatives, namely, 4-Amino-6-substituted benzyl-3-(2-substituted benzylidenehydrazinyl)-1,2,4-triazin-5(4H)-ones and acetylated 6-substituted benzyl-7-oxo-3-substituted phenyl-2,3-dihydro-7H-[1,2,4]triazolo[4,3-b][1,2,4] triazine analogs were utilized for the prediction of the QSAR model. Furthermore, the application of this QSAR equation served successfully as a rational guide for predicting the activities of newly synthesized analogs. The DFT calculation was applied to recognize the physicochemical parameters at B3LYP/6- 311G* level to gain a clear view of global and local molecular reactivity. Besides, the molecular features of the investigated compounds were identified through HOMO, LUMO and molecular electrostatic potential (MEP) which were plotted to determine the charge transfer within the molecules. Promising two novel 1,2,4-triazine compounds were identified with observed significant inhibitions (83% and 67%) and CYP1A1 activity was predicted. The chemical configuration of the two actives showed good alignment of
p-methoxy benzyl aminotriazinone fragments, hydrazino and carbonyl linker in structure–activity relationship and interaction. Molecular modeling analysis supported with MD simulations was undertaken to investigate different binding interactions with the target binding site. These projects offered a good application of a promising QSAR model for prediction of highly active compounds for further lead optimization.